Cardiometabolic Disease

The CST therapeutic platform originated from discoveries demonstrating the peptide's important roles in blood-pressure regulation, glucose and lipid metabolism, insulin sensitivity, inflammation, and cardiovascular homeostasis.

Preclinical studies have shown that CST can reduce elevated blood pressure, improve glucose tolerance and insulin sensitivity, promote lipid utilization, reduce hepatic lipid accumulation, and attenuate inflammatory responses.

These findings support continued development of CST-based therapeutics for hypertension, obesity, diabetes, and associated cardiovascular and metabolic disorders.